WO2012016314A9 - Composés dérivés de l'acide arachidonique et substitués avec des analogues de coxibs pour le traitement de la douleur - Google Patents

Composés dérivés de l'acide arachidonique et substitués avec des analogues de coxibs pour le traitement de la douleur Download PDF

Info

Publication number
WO2012016314A9
WO2012016314A9 PCT/BR2011/000275 BR2011000275W WO2012016314A9 WO 2012016314 A9 WO2012016314 A9 WO 2012016314A9 BR 2011000275 W BR2011000275 W BR 2011000275W WO 2012016314 A9 WO2012016314 A9 WO 2012016314A9
Authority
WO
WIPO (PCT)
Prior art keywords
derived
arachidonic acid
substituted compounds
treating pain
coxib
Prior art date
Application number
PCT/BR2011/000275
Other languages
English (en)
Portuguese (pt)
Other versions
WO2012016314A1 (fr
Inventor
André AUGUSTO GOMES FARACO
Janetti Nogueira De Francischi
Rafael Machado Rezende
Patrícia PAIVA LIMA
Webster Glayser Pimenta Dos Reis
Original Assignee
Universidade Federal De Minas Gerais - Ufmg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Minas Gerais - Ufmg filed Critical Universidade Federal De Minas Gerais - Ufmg
Publication of WO2012016314A1 publication Critical patent/WO2012016314A1/fr
Publication of WO2012016314A9 publication Critical patent/WO2012016314A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La présente invention concerne l'obtention de composés dérivés de l'acide arachidonique et substitués avec des analogues de coxibs, ainsi que leurs sels, pour le traitement de la douleur. L'invention concerne également des compositions pharmaceutiques contenant des composés dérivés de l'acide arachidonique et substitués avec des analogues de coxibs, leurs sels et des excipients pharmaceutiquement acceptables pour le traitement de la douleur. Les analgésiques de l'invention peuvent être utilisés de manière isolée ou en association avec d'autres analgésiques, pour atténuer la douleur légère, modérée ou sévère.
PCT/BR2011/000275 2010-08-04 2011-08-04 Composés dérivés de l'acide arachidonique et substitués avec des analogues de coxibs pour le traitement de la douleur WO2012016314A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI1003050-6A BRPI1003050B1 (pt) 2010-08-04 2010-08-04 Compostos derivados do ácido araquidônico substituídos com análogos de coxibes para tratamento de dor
BRPI1003050-6 2010-08-04

Publications (2)

Publication Number Publication Date
WO2012016314A1 WO2012016314A1 (fr) 2012-02-09
WO2012016314A9 true WO2012016314A9 (fr) 2012-03-22

Family

ID=45558870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000275 WO2012016314A1 (fr) 2010-08-04 2011-08-04 Composés dérivés de l'acide arachidonique et substitués avec des analogues de coxibs pour le traitement de la douleur

Country Status (2)

Country Link
BR (1) BRPI1003050B1 (fr)
WO (1) WO2012016314A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7161016B1 (en) * 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US20040122089A1 (en) * 2001-06-20 2004-06-24 Martin Billy R. Novel eicosanoid analgesics
US20040092566A1 (en) * 2002-11-12 2004-05-13 Graneto Matthew J. Celecoxib prodrug
US20070105940A1 (en) * 2005-10-19 2007-05-10 Allergan, Inc. Method for treating pain

Also Published As

Publication number Publication date
BRPI1003050B1 (pt) 2021-05-25
BRPI1003050A2 (pt) 2014-03-25
WO2012016314A1 (fr) 2012-02-09

Similar Documents

Publication Publication Date Title
WO2013170068A3 (fr) Modulateurs du transport nucléaire et leurs utilisations
WO2012055567A3 (fr) Utilisation de malononitrilamides dans la douleur neuropathique
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
WO2012075362A3 (fr) Modulateurs du récepteur cxcr4 de la chimiokine et leurs utilisations
WO2011085162A3 (fr) Compositions topiques transdermiques de dexmédétomidine et leurs procédés d'utilisation
WO2012098562A3 (fr) Compositions liquides pour administration par voie orale de sels de lanthane
WO2015056094A3 (fr) Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent analgésique
IL251543A0 (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
WO2012053013A3 (fr) Compositions pharmaceutiques d'agents anti-acné
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2014011750A8 (fr) Formulations de laquinimod sans agent alcalinisant
SG10201501579WA (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurennine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
MX363389B (es) Composicion farmaceutica que comprende ivabradina amorfa.
WO2014071168A3 (fr) Administration d'inhibiteurs de la signalisation tgfbêta, dérivés de benzothiazépine ou combinaisons de ceux-ci pour améliorer la fonction musculaire chez des patients cancéreux
WO2013087654A3 (fr) Méthodes de prévention ou de traitement de troubles par l'augmentation de la biodisponibilité du fer et formulation pharmaceutique associée
WO2012085249A3 (fr) Formes pharmaceutiques orales homogènes comprenant de la lercanidipine et de l'énalapril ou leurs sels pharmaceutiquement acceptables
WO2012029074A3 (fr) Compositions pharmaceutiques de linézolide
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
WO2012016314A9 (fr) Composés dérivés de l'acide arachidonique et substitués avec des analogues de coxibs pour le traitement de la douleur
WO2013038200A3 (fr) Troubles neurodéveloppementaux
WO2011107921A3 (fr) Composition de milnacipran à libération modifiée
WO2014013090A3 (fr) Formulation comprenant du fingolimod amorphe
WO2013072770A3 (fr) Formulations pharmaceutiques comprenant de l'atorvastatine et du glimépiride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813972

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813972

Country of ref document: EP

Kind code of ref document: A1